Photo from FDA Oncology/X
Mar 15, 2024, 18:07
Talazoparib in Combination With Enzalutamide for Prostate Cancer – FDA Oncology
FDA Oncology posted on X/Twitter:
“FDA Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer – Journal of Clinical Oncology. 1st author Brian Heiss, last author Daniel Suzman.“
View additional information.
Source: FDA Oncology/X